» Articles » PMID: 24376746

Overexpression of CUGBP1 in Skeletal Muscle from Adult Classic Myotonic Dystrophy Type 1 but Not from Myotonic Dystrophy Type 2

Overview
Journal PLoS One
Date 2013 Dec 31
PMID 24376746
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Myotonic dystrophy type 1 (DM1) and type 2 (DM2) are progressive multisystemic disorders caused by similar mutations at two different genetic loci. The common key feature of DM pathogenesis is nuclear accumulation of mutant RNA which causes aberrant alternative splicing of specific pre-mRNAs by altering the functions of two RNA binding proteins, MBNL1 and CUGBP1. However, DM1 and DM2 show disease-specific features that make them clearly separate diseases suggesting that other cellular and molecular pathways may be involved. In this study we have analysed the histopathological, and biomolecular features of skeletal muscle biopsies from DM1 and DM2 patients in relation to presenting phenotypes to better define the molecular pathogenesis. Particularly, the expression of CUGBP1 protein has been examined to clarify if this factor may act as modifier of disease-specific manifestations in DM. The results indicate that the splicing and muscle pathological alterations observed are related to the clinical phenotype both in DM1 and in DM2 and that CUGBP1 seems to play a role in classic DM1 but not in DM2. In conclusion, our results indicate that multisystemic disease spectrum of DM pathologies may not be explained only by spliceopathy thus confirming that the molecular pathomechanism of DM is more complex than that actually suggested.

Citing Articles

Curriculum vitae of CUG binding protein 1 (CELF1) in homeostasis and diseases: a systematic review.

Qin W, Shi J, Chen R, Li C, Liu Y, Lu J Cell Mol Biol Lett. 2024; 29(1):32.

PMID: 38443798 PMC: 10916161. DOI: 10.1186/s11658-024-00556-y.


Aerobic exercise elicits clinical adaptations in myotonic dystrophy type 1 patients independently of pathophysiological changes.

Mikhail A, Nagy P, Manta K, Rouse N, Manta A, Ng S J Clin Invest. 2022; 132(10).

PMID: 35316212 PMC: 9106360. DOI: 10.1172/JCI156125.


An overview of the molecular and physiological antidepressant mechanisms of physical exercise in animal models of depression.

de Oliveira L, Machado F, Rocha-Dias I, Magalhaes C, De Sousa R, Cassilhas R Mol Biol Rep. 2022; 49(6):4965-4975.

PMID: 35092564 DOI: 10.1007/s11033-022-07156-z.


Epigenetics of Myotonic Dystrophies: A Minireview.

Visconti V, Centofanti F, Fittipaldi S, Macri E, Novelli G, Botta A Int J Mol Sci. 2021; 22(22).

PMID: 34830473 PMC: 8623789. DOI: 10.3390/ijms222212594.


Myotonic dystrophy type 2: the 2020 update.

Meola G Acta Myol. 2021; 39(4):222-234.

PMID: 33458578 PMC: 7783423. DOI: 10.36185/2532-1900-026.


References
1.
Day J, Ricker K, Jacobsen J, Rasmussen L, Dick K, Kress W . Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology. 2003; 60(4):657-64. DOI: 10.1212/01.wnl.0000054481.84978.f9. View

2.
Botta A, Caldarola S, Vallo L, Bonifazi E, Fruci D, Gullotta F . Effect of the [CCTG]n repeat expansion on ZNF9 expression in myotonic dystrophy type II (DM2). Biochim Biophys Acta. 2005; 1762(3):329-34. DOI: 10.1016/j.bbadis.2005.11.004. View

3.
Ranum L, Cooper T . RNA-mediated neuromuscular disorders. Annu Rev Neurosci. 2006; 29:259-77. DOI: 10.1146/annurev.neuro.29.051605.113014. View

4.
Huichalaf C, Schoser B, Schneider-Gold C, Jin B, Sarkar P, Timchenko L . Reduction of the rate of protein translation in patients with myotonic dystrophy 2. J Neurosci. 2009; 29(28):9042-9. PMC: 3610333. DOI: 10.1523/JNEUROSCI.1983-09.2009. View

5.
Bachinski L, Czernuszewicz T, Ramagli L, Suominen T, Shriver M, Udd B . Premutation allele pool in myotonic dystrophy type 2. Neurology. 2008; 72(6):490-7. PMC: 2677510. DOI: 10.1212/01.wnl.0000333665.01888.33. View